Jasmine Kamboj and Jonathan Ticku
May 29, 2025, 20:53
Jasmine Kamboj Congratulated Jonathan Ticku for FDA ODAC Testimony on Daratumumab
Jasmine Kamboj, Medical Oncologist and Hematologist at the Mayo Clinic, shared a post on LinkedIn by Jonathan Ticku, Assistant Professor of Oncology at the Mayo Clinic and GU Oncology Lead at the Mayo Clinic Health System, adding:
“Congratulations Jonathan Ticku, M.D. for this crucial endeavor.
So honored to be working with you at Mayo Clinic, FDA.
Can’t wait for ASCO 2025 next week, and have you as our panelist for the policy discussion.”
Quoting Jonathan Ticku‘s post:
“This week I had the opportunity to give testimony to the FDA Oncologic Drugs Advisory Committee (ODAC) in support of daratumumab for high risk smoldering myeloma. I was able to represent the perspective and challenges of practicing community hematologists and oncologists.
The ODAC voted in favor (6:2) for daratumumab use in high-risk smoldering myeloma, based on the results of the AQUILA study.”
Read ‘ODAC Votes Daratumumab Benefits Smoldering MM’.
Learn more about Daratumumab for Smoldering Myeloma on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 19:09
May 29, 2025, 17:58
May 29, 2025, 17:45